Air Methods (NASDAQ: AIRM) and China Cord Blood (NYSE:CO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
This table compares Air Methods and China Cord Blood’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|China Cord Blood||26.79%||9.68%||4.36%|
9.1% of China Cord Blood shares are owned by institutional investors. 9.0% of Air Methods shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for Air Methods and China Cord Blood, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|China Cord Blood||0||0||0||0||N/A|
Air Methods currently has a consensus target price of $43.00, indicating a potential upside of 0.12%. Given Air Methods’ higher possible upside, research analysts clearly believe Air Methods is more favorable than China Cord Blood.
Earnings and Valuation
This table compares Air Methods and China Cord Blood’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|China Cord Blood||$110.41 million||9.68||$18.33 million||$0.35||25.32|
China Cord Blood has higher revenue and earnings than Air Methods. Air Methods is trading at a lower price-to-earnings ratio than China Cord Blood, indicating that it is currently the more affordable of the two stocks.
Air Methods beats China Cord Blood on 6 of the 10 factors compared between the two stocks.
About Air Methods
Air Methods Corporation is engaged in providing air medical emergency transport services and systems throughout the United States. The Company’s segments include Air Medical Services (AMS), Tourism and United Rotorcraft (UR) Division. As of December 31, 2016, its AMS Division provided air medical transportation services in 41 states to the general population as an independent service (also called community-based services) and to hospitals or other institutions under exclusive operating agreements (also called hospital-based services). It transports persons requiring intensive medical care from either the scene of an accident or general care hospitals to skilled trauma centers or tertiary care centers. As of December 31, 2016, its Air Medical Services Division operated 394 helicopters and 31 fixed wing aircrafts under both Instrument Flight Rules (IFR) and Visual Flight Rules (VFR). As of December 31, 2016, its Tourism Division operated 63 helicopters and two fixed wing aircrafts.
About China Cord Blood
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants. As of March 31, 2016, the Company had three operating cord blood banks.
Receive News & Ratings for Air Methods Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Air Methods and related companies with MarketBeat.com's FREE daily email newsletter.